Intas Pharmaceuticals Ltd — olaparib (Phase II Trial Completion)

Therapy area: Oncology. Indication: Breast Cancer, Castration-Resistant Prostate Cancer (CRPC), Epithelial Ovarian Cancer, Fallopian Tube Cancer, Metastatic Breast Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Peritoneal Cancer, Solid Tumor